// App-Quantinova.ai

S148 : ACALABRUTINIB ± OBINUTUZUMAB VS OBINUTUZUMAB + CHLORAMBUCIL IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA: ELEVATE-TN 4-YEAR FOLLOW-UP

Researchers

Presenter

  • Jeff Sharman

Principal Investigators

  • Wojciech Jurczak

  • Alan Skarbnik

  • John M. Pagel

  • Ian W. Flinn

  • Manali Kamdar

  • Munir Munir

  • Renata Walewska

  • Gillian Corbett

  • Laura Maria Fogliatto

  • Yair Herishanu

  • Versha Banerji

  • Steven Coutre

  • George Follows

  • Patricia Walker

  • Karin Karlsson

  • Paolo Ghia

  • Ann Janssens

  • Florence Cymbalista

  • Jennifer A. Woyach

  • Emmanuelle Ferrant

  • William G. Wierda

  • Veerendra Munugalavadla

  • Priti Patel

  • Min Hui Wang

  • John C Byrd

Medical Centers

  • Peninsula Health and Peninsula Private Hospital, Frankston,Melbourne,Australia

  • Urologie, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • Swedish Cancer Institute, Seattle, Washington, United States

  • Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel

  • Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba and CancerCare Manitoba,Winnipeg,Canada

  • Haematology, Haematological Malignancy Diagnostic Service (HMDS), St. James's Institute of Oncology, Leeds, UK

  • Willamette Valley Cancer Institute and Research Center, Springfield, OR

  • Somogy County Mór Kaposi General Hospital, Kaposvár, Hungary

  • Stanford School of Medicine, Stanford, CA

  • Lund University Hospital, Lund, Sweden

  • The Ohio State University Comprehensive Cancer Center, Columbus, OH

  • Hospital De Clinicas de Porto Alegre, Porto Alegre RS, Brazil

  • AstraZeneca,South San Francisco, CA,United States

  • Levine Cancer Institute,Charlotte,United States

  • Tauranga Hospital, Tauranga, New Zealand

  • University of Colorado Cancer Center,Aurora, CO,Verenigde Staten

  • Bobigny: Hématologie, CHU Avicennes,Bobigny,France

  • Cancer Care, University Hospitals Dorset,Bournemouth,United Kingdom

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Sarah Cannon Research Institute, Nashville,United States

  • Addenbrookes Hospital, Cambridge, United Kingdom

Locations

  • Australia

  • France

  • Poland

  • United States

  • Israel

  • Canada

  • United Kingdom

  • Hungary

  • Sweden

  • Brazil

  • New Zealand

  • Italy

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • ACP-196

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • chlorambucil

Outcome

  • N/A

Study Design

  • Cross Over

Phase

  • NA

Study Id's

  • NCT02475681

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved